CA3038019A1 - Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer - Google Patents
Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer Download PDFInfo
- Publication number
- CA3038019A1 CA3038019A1 CA3038019A CA3038019A CA3038019A1 CA 3038019 A1 CA3038019 A1 CA 3038019A1 CA 3038019 A CA3038019 A CA 3038019A CA 3038019 A CA3038019 A CA 3038019A CA 3038019 A1 CA3038019 A1 CA 3038019A1
- Authority
- CA
- Canada
- Prior art keywords
- active ingredient
- combination
- chemical formula
- cancer
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 34
- 229940079156 Proteasome inhibitor Drugs 0.000 title claims abstract description 21
- 201000011510 cancer Diseases 0.000 title claims abstract description 21
- 239000003207 proteasome inhibitor Substances 0.000 title claims abstract description 21
- 229940124622 immune-modulator drug Drugs 0.000 title claims abstract description 17
- 230000002489 hematologic effect Effects 0.000 title claims abstract description 15
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract description 11
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract description 7
- 238000011282 treatment Methods 0.000 title description 4
- 239000000126 substance Substances 0.000 claims abstract description 47
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- 230000003637 steroidlike Effects 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims description 72
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 29
- 229960003957 dexamethasone Drugs 0.000 claims description 29
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 23
- 229960001467 bortezomib Drugs 0.000 claims description 19
- 229960004942 lenalidomide Drugs 0.000 claims description 19
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract description 9
- 108090000353 Histone deacetylase Proteins 0.000 abstract description 9
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 230000001988 toxicity Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000004526 pharmaceutical effect Effects 0.000 abstract description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 230000001093 anti-cancer Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- -1 catechin-3-galate Chemical compound 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 4
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 4
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000012447 xenograft mouse model Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229950002736 marizomib Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940099039 velcade Drugs 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010029783 Normochromic normocytic anaemia Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000001446 anti-myeloma Effects 0.000 description 1
- 239000012635 anticancer drug combination Substances 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical group CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N epoxomicin Chemical compound CC[C@H](C)[C@H](N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 DOGIDQKFVLKMLQ-JTHVHQAWSA-N 0.000 description 1
- 108700002672 epoxomicin Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a pharmaceutical combination for treating a hematological cancer comprising the histone deacetylase (HDAC) inhibitor of the chemical formula 1, a proteasome inhibitor or an immunomodulatory drug and a steroidal anti-cancer agent together.The pharmaceutical combination of the present invention can be useful for treating a hematological cancer such as multiple myeloma, by reducing toxicity which is the problem of the conventional HDAC inhibitor and exhibiting an equivalent level of pharmaceutical effects due to a complex inhibitory mechanism against the cancer of the compound of chemical formula 1 and its pharmaceutically acceptable salt, the proteasome inhibitor or the immunomodulatory drug and the steroidal anti-cancer agent.
Description
Description Title of Invention: PHARMACEUTICAL COMBINATIONS OF
HISTONE DEACETYLASE INHIBITOR AND PROTEASOME
INHIBITOR OR IMMUNOMODULATORY DRUG FOR THE
TREATMENT OF HEMATOLOGICAL CANCER
Technical Field [1-1 The present invention relates to a pharmaceutical combination for treating a hema-tological cancer, more specifically, multiple myeloma, particularly, a hematological cancer which is resistant to conventional therapies, and more specifically, relates to a pharmaceutical combination for treating myeloma comprising a histone deacetylase (HDAC) inhibitor, a proteasome inhibitor or an immunomodulatory drug and a steroidal anti-cancer agent together.
Background Art
HISTONE DEACETYLASE INHIBITOR AND PROTEASOME
INHIBITOR OR IMMUNOMODULATORY DRUG FOR THE
TREATMENT OF HEMATOLOGICAL CANCER
Technical Field [1-1 The present invention relates to a pharmaceutical combination for treating a hema-tological cancer, more specifically, multiple myeloma, particularly, a hematological cancer which is resistant to conventional therapies, and more specifically, relates to a pharmaceutical combination for treating myeloma comprising a histone deacetylase (HDAC) inhibitor, a proteasome inhibitor or an immunomodulatory drug and a steroidal anti-cancer agent together.
Background Art
[2] Myeloma of hematological cancers refers to a tumor consisting of cells of the type usually found in bone marrow. Furthermore, multiple myeloma (MM) means dis-seminated malignant neoplasm of plasma cells characterized by secretion of multiple myeloid tumor lesions and M component (monoclonal immunoglobulin fragment), related to widespread osteolytic lesions that lead to bone pain, pathological fractures, hypercalcemia and normocytic normochromic anemia. Multiple myeloma cannot be treated by conventional, high-dose chemotherapies.
[31 On the other hand, acetylation status of nucleosomal histones plays an important role in the regulation of gene expression. Deacetylation of nucleosomal histones is fa-cilitated by a group of enzymes known as histone deacetylases (HDACs) with 11 known isoforms. Histone deacetylation induces chromatin condensation leading to transcriptional repression, while acetylation allows approaching to transcriptional machinery which makes transcription easy by inducing localized relaxation within specific chromosomal regions. In tumor cells, selective inhibitors of HDAC
enzymes lead to histone hyperacetylation. It is known to alter transcriptional regulation of a subset of genes, including many tumor suppressor genes involved in cell cycle control, cell division and apoptosis. In addition, HDAC inhibitors have been reported to inhibit tumor growth in vivo. Inhibition of tumor growth is accompanied by hyperacetylation of histone and tubulin and may include a number of mechanisms. HDAC inhibitors block cancer cell proliferation in both in vitro and in vivo. As described above, it has been known that HDAC inhibitors effectively inhibit cancer growth in multiple myeloma, but in case of drugs developed in the past, there is a problem that their use is limited due to severe toxicity.
[4] On the other hand, proteasome inhibitors and immunomodulatory drugs are well known as the main agents for treating multiple myeloma.
151 Meanwhile, immunomoduratory (IMiD) class of drugs exhibit significant anti-myeloma characteristics in various multiple myeloma models and have been shown to have significant clinical activity in patients with multiple myeloma. Among these, bortezomib (also known as Velcade or PS-341) has been reported to have activity in NSCLS cell lines as an FDA-approved small molecule proteasome inhibitor in treatment of refractory multiple myeloma, where it was found to induce concentration and time-dependent G2/M cell cycle arrest.
[6] Due to various problems of these therapies including toxicity, there is a strong need for a combination and a method that are more effective and less toxic for treating multiple myeloma.
Disclosure of Invention Technical Problem 171 Under these circumstances, the present inventors have conducted intensive studies on a more effective and less toxic hematological cancer drug, specifically multiple myeloma. As a result, the present invention has been completed by confirming that in case of combining the compound of chemical formula 1 as a HDAC inhibitor and a proteasome inhibitor or an immunomodulatory drug and a steroidal anti-cancer agent.
It is possible to obtain synergistic anti-cancer effect with reduced toxicity and comparable pharmaceutical effect to other HDAC inhibitors in multiple myeloma, which has been difficult to effectively treat due to various problems such as toxicity, etc. in the past.
[81 Thus, the purpose of the present invention is to provide a composition for treating myeloma comprising the compound of the following chemical formula 1 as a histone deacetylase inhibitor, a proteasome inhibitor or an immunomodulatory drug, and a steroidal anti-cancer agent.
Solution to Problem 191 As one embodiment to achieve the above purpose, the present invention relates to a pharmaceutical combination for treating a hematological cancer comprising, [10] 1) a hydroxamic acid derivative represented by the following chemical formula 1, N-(7-(hydroxyamino)-7-oxohepty1)-4-methyl-N-(4-(1-methy1-1H-indazol-6-y1)phenyl)pi perazine-l-carboxamide methanesulfonate or its pharmaceutically acceptable salt as the first active ingredient;
[11] 2) a proteasome inhibitor or an immunomodulatory drug as the second active in-gredient; and
[31 On the other hand, acetylation status of nucleosomal histones plays an important role in the regulation of gene expression. Deacetylation of nucleosomal histones is fa-cilitated by a group of enzymes known as histone deacetylases (HDACs) with 11 known isoforms. Histone deacetylation induces chromatin condensation leading to transcriptional repression, while acetylation allows approaching to transcriptional machinery which makes transcription easy by inducing localized relaxation within specific chromosomal regions. In tumor cells, selective inhibitors of HDAC
enzymes lead to histone hyperacetylation. It is known to alter transcriptional regulation of a subset of genes, including many tumor suppressor genes involved in cell cycle control, cell division and apoptosis. In addition, HDAC inhibitors have been reported to inhibit tumor growth in vivo. Inhibition of tumor growth is accompanied by hyperacetylation of histone and tubulin and may include a number of mechanisms. HDAC inhibitors block cancer cell proliferation in both in vitro and in vivo. As described above, it has been known that HDAC inhibitors effectively inhibit cancer growth in multiple myeloma, but in case of drugs developed in the past, there is a problem that their use is limited due to severe toxicity.
[4] On the other hand, proteasome inhibitors and immunomodulatory drugs are well known as the main agents for treating multiple myeloma.
151 Meanwhile, immunomoduratory (IMiD) class of drugs exhibit significant anti-myeloma characteristics in various multiple myeloma models and have been shown to have significant clinical activity in patients with multiple myeloma. Among these, bortezomib (also known as Velcade or PS-341) has been reported to have activity in NSCLS cell lines as an FDA-approved small molecule proteasome inhibitor in treatment of refractory multiple myeloma, where it was found to induce concentration and time-dependent G2/M cell cycle arrest.
[6] Due to various problems of these therapies including toxicity, there is a strong need for a combination and a method that are more effective and less toxic for treating multiple myeloma.
Disclosure of Invention Technical Problem 171 Under these circumstances, the present inventors have conducted intensive studies on a more effective and less toxic hematological cancer drug, specifically multiple myeloma. As a result, the present invention has been completed by confirming that in case of combining the compound of chemical formula 1 as a HDAC inhibitor and a proteasome inhibitor or an immunomodulatory drug and a steroidal anti-cancer agent.
It is possible to obtain synergistic anti-cancer effect with reduced toxicity and comparable pharmaceutical effect to other HDAC inhibitors in multiple myeloma, which has been difficult to effectively treat due to various problems such as toxicity, etc. in the past.
[81 Thus, the purpose of the present invention is to provide a composition for treating myeloma comprising the compound of the following chemical formula 1 as a histone deacetylase inhibitor, a proteasome inhibitor or an immunomodulatory drug, and a steroidal anti-cancer agent.
Solution to Problem 191 As one embodiment to achieve the above purpose, the present invention relates to a pharmaceutical combination for treating a hematological cancer comprising, [10] 1) a hydroxamic acid derivative represented by the following chemical formula 1, N-(7-(hydroxyamino)-7-oxohepty1)-4-methyl-N-(4-(1-methy1-1H-indazol-6-y1)phenyl)pi perazine-l-carboxamide methanesulfonate or its pharmaceutically acceptable salt as the first active ingredient;
[11] 2) a proteasome inhibitor or an immunomodulatory drug as the second active in-gredient; and
3 [12] 3) a steroidal anti-cancer agent as the third active ingredient.
Preferably, the hema-tological cancer is multiple myeloma.
[13] [Chemical formula 11 [14]
N/=N 0 i 40 N "-''''.'-'-'='--''')1" N '()1/
H
0..)-"N1 OH
1-....õ....N, -S=0 II
Advantageous Effects of Invention [15] The improved efficacy of the combination according to the present invention can be demonstrated by measuring the therapeutic synergistic effect. The combination of the present invention exhibits a synergistic effect when the first active ingredient, which is a HDAC inhibitor, is administered in combination with the second active ingredient and the third active ingredient, and thus has excellent anti-cancer activity against a hematological cancer, particularly multiple myeloma.
Brief Description of Drawings [16] FIG. la is a graph of cancer growth of the control group and each experimental group in MM. is xenograft mouse model.
[17] FIG. lb shows the tumor size change by individual of each experimental group on the last day of the experiment (day 57) in MM. is xenograft mouse model.
[18] FIG. 2a is a graph of cancer growth of the control group and each experimental group in MM. is xenograft mouse model.
[19] FIG. 2b shows the tumor size change by individual of each experimental group on the last day of the experiment (day 70) in MM. is xenograft mouse model.
Best Mode for Carrying out the Invention [20] Hereinafter, the present invention will be described in more detail.
[21] The first active ingredient of the pharmaceutical combination according to the present invention is the compound of the above chemical formula 1, and this compound has activity as a histone deacetylase (HDAC). The description and preparation method of the compound of the above chemical formula 1 are described in detail in international patent publication No. WO 2010-110545, which is incorporated
Preferably, the hema-tological cancer is multiple myeloma.
[13] [Chemical formula 11 [14]
N/=N 0 i 40 N "-''''.'-'-'='--''')1" N '()1/
H
0..)-"N1 OH
1-....õ....N, -S=0 II
Advantageous Effects of Invention [15] The improved efficacy of the combination according to the present invention can be demonstrated by measuring the therapeutic synergistic effect. The combination of the present invention exhibits a synergistic effect when the first active ingredient, which is a HDAC inhibitor, is administered in combination with the second active ingredient and the third active ingredient, and thus has excellent anti-cancer activity against a hematological cancer, particularly multiple myeloma.
Brief Description of Drawings [16] FIG. la is a graph of cancer growth of the control group and each experimental group in MM. is xenograft mouse model.
[17] FIG. lb shows the tumor size change by individual of each experimental group on the last day of the experiment (day 57) in MM. is xenograft mouse model.
[18] FIG. 2a is a graph of cancer growth of the control group and each experimental group in MM. is xenograft mouse model.
[19] FIG. 2b shows the tumor size change by individual of each experimental group on the last day of the experiment (day 70) in MM. is xenograft mouse model.
Best Mode for Carrying out the Invention [20] Hereinafter, the present invention will be described in more detail.
[21] The first active ingredient of the pharmaceutical combination according to the present invention is the compound of the above chemical formula 1, and this compound has activity as a histone deacetylase (HDAC). The description and preparation method of the compound of the above chemical formula 1 are described in detail in international patent publication No. WO 2010-110545, which is incorporated
4 herein by reference. In the present invention, the compound of the above chemical formula 1 can be prepared by the preparation method disclosed in the above document.
Generally, it is known that the compound of the above chemical formula 1 ad-ministered to humans varies in dosage depending on various administration factors including individual specific factors of patients, but for example, it can be administered in 10 to 210 mg/m2.
[22] On the other hand, the second active ingredient of the pharmaceutical combination according to the present invention is a proteasome inhibitor or an immunomodulatory drug, and the proteasome inhibitor is an agent inhibiting activity of a proteasome (i.e. a cell complex degrading a protein) degrading a cell division regulating protein reversely, and it is based on the fact that the normal cells regenerate cell division ability even if the activity of the proteasome is temporarily inhibited, but various cancer cells enter the death process as soon as the proteasome activity is temporarily inhibited. The proteasome inhibitor that may be comprised in the pharmaceutical com-bination of the present invention may be various classes of known proteasome in-hibitors. For example, as a class of peptide boronate, there is bortezomib (INN, PS0341; Velcade) which is a compound approved in the United States for treating relapsed multiple myeloma. There is CEP-18770, as another peptide boronate. As other classes of proteasome inhibitors, there are peptide aldehyde (for example, MG132), peptide vinyl sulfone, peptide epoxyketone (for example, epoxomicin, carfilzomib), p lactone inhibitor (for example, lactocystine, MLN 519, NPI-0052, salinosporamide A), a compound which produces dithiocarbamate complex with a metal (for example, disulfiram which is also used in treatment of chronic alcoholism), and specific an-tioxidant (for example, epigallocatechin-3-gallate, catechin-3-galate, and sali-nosporamide A. The proteasome inhibitor comprised in the pharmaceutical com-bination of the present invention is preferably, bortezomib represented by the following chemical formula 2 or its pharmaceutically acceptable salt. The bortezomib can be administered intravenously or subcutaneously in a dose of 0.3-1.5 mg/m2, 1 to 2 times per week, depending on the administration schedule, but is not limited thereto.
[23] [Chemical formula 21 [24]
0004,4%.
N
[251 Meanwhile, the immunomodulatory drug has effects such as expansion of immune cells and promotion of tumor cell death, etc. and specifically, a substance which regulates immunity by improving ADCC (antibody-dependent cell-mediated cyto-toxicity). Specifically, the immunomodulatory drug comprised in the pharmaceutical combination of the present invention may be thalidomide lenalidomide, for-malidomide, or a pharmaceutically acceptable salt, and preferably, lenalidomide rep-resented by the following chemical formula 3 or its pharmaceutically acceptable salt.
Lenalidomide is generally orally administered in a dose of 10 mg to 30 mg depending on the administration schedule, but is not limited thereto.
[26] [Chemical formula 31 [27]
a [28]
[29] The third active ingredient of the pharmaceutical combination according to the present invention is a steroidal anti-cancer agent, and for example, may be prednisone or dexamethasone, but is not limited thereto. Preferably, dexamethasone represented by the following chemical formula 4 that is, (8S, 9R, 10S, 11S, 13S, 14S, 16R, 17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacety1)-10,13,16-trimethy1-6,7,8,9,10,11 ,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene- 3-on or isotope variant; or its pharmaceutically acceptable salt, hydrate, or solvate. In one em-bodiment, dexamethasone is (8S, 9R, 10S, 11S, 13S, 14S, 16R, 17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacety1)-10,13,16-trimethy1-6,7,8,9,10,11 ,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3-on. In other em-bodiment, dexamethasone is (8S, 9R, 10S, 11S, 13S, 14S, 16R, 17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacety1)-10,13,16-trimethy1-6,7,8,9,10,11 ,12,13,14,15,16,17- dodecahydro-3H-cyclopenta[a]phenanthrene-3-on, wherein hydrogen atom is deuterated.
[30] [Chemical formula 41 [31]
V 1' O 0 H
[32] In the present invention, the pharmaceutically acceptable salt means a salt commonly used in the medical industry, and for example, there are inorganic ionic salts prepared with calcium, potassium, sodium and magnesium, etc., inorganic acid salts prepared with hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid, tartaric acid and sulfuric acid, etc., organic acid salts prepared with acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, etc., amino acid salts prepared with methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, p-toluene sulfonic acid and naphthalene sulfonic acid, etc., and amine salts prepared with trimethylamine, triethylamine, ammonia, pyridine, picoline, etc., but the kinds of salts in the present invention are not limited by these listed salts.
[33] In one specific embodiment, the first active ingredient, the second active ingredient, and the third active ingredient may be comprised per 100 parts by weight of the total pharmaceutical combination. When a proteasome inhibitor such as bortezomib is used as the second active ingredient, it is composed of 28.55 to 85.60 parts by weight of the first active ingredient, 1.28 to 8.63 parts by weight of the second active ingredient and 2.71 to 69.55 parts by weight of the third active ingredient. When an im-munomodulatory drug such as lenalidomide is used as the second active ingredient, it is composed of 19.54 to 94.69 parts by weight of the first active ingredient, 2.46 to 52.63 parts by weight of the second active ingredient and 2.52 to 59.70 parts by weight of the third active ingredient.
[34] The pharmaceutical combination may comprise 3 kinds of separate formulations, and may consist of two or one formulation.
[35] The combination of the present invention may be administered orally or parenterally (For example, intravenously, subcutaneously, intraperitoneally or topically).
In the present invention, the first active ingredient and the second active ingredient may be administered orally or parenterally, and preferably, may be administered parenterally.
In addition, the third active ingredient may be parenterally or orally administered, preferably administered orally.
[36] In the combination of the present invention, the range of appropriate dose of the first active ingredient to the third active ingredient varies according to the body weight, age, sex, health condition of patient, diet, administration time, administration method, excretion rate, and severity of disease, etc. The daily dose of the first active ingredient is approximately 10 ¨ 80 mg/kg, preferably 20 to 60 mg/kg. In addition, the daily dose of the second active ingredient of the present invention is approximately 0.1 ¨ 5 mg/
kg, preferably 0.5 to 2 mg/kg.
[37] In the combination of the present invention, the appropriate administration period of the first active ingredient and the second active ingredient and the third active in-gredient may be determined according to the dose. For example, in case that the second active ingredient of the present invention is a proteasome inhibitor, the first active in-gredient may be administered once a day to once every two weeks, preferably once a week. In addition, the second active ingredient of the present invention may be ad-ministered once a day to once a week, preferably twice a week. The third active in-gredient of the present invention may be administered once a day to once a week, preferably 4 times a week. In addition, in case that the second active ingredient of the present invention is an immunomodulatory drug, the first active ingredient of the present invention may be administered once a day to once every two weeks, preferably once a week, and the second active ingredient may be administered once a day to once a week, preferably once a day, and the third active ingredient may be administered once a day to once a week, preferable once a week.
[38] The pharmaceutical combination of the present invention confirmed the combination effect of the first active ingredient, which is a HDAC inhibitor, the second active in-gredient, which is a proteasome inhibitor or an immunomodulatory drug, and the third active ingredient, which is a steroidal anti-cancer agent, thereby exhibiting excellent anti-cancer activity.
[39] Therefore, the anti-cancer combination of the present invention can by usefully used as an anti-cancer treatment strategy, and it is preferable particularly for treating a hematological cancer. The hematological cancer may preferably be multiple myeloma.
[40] In the present invention, the first active ingredient, the second active ingredient, and the third active ingredient comprised in the combination of the present invention may be comprised in separate pharmaceutical composition respectively, and the pharma-ceutical composition may be prepared in a unit dose form or prepared by introducing in a multi-dose container by formulating it using a pharmaceutically acceptable carrier, according to a method which can be easily carried out by a person having ordinary skill in the art.
[41] The pharmaceutically acceptable carrier is conventionally used in formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxy-benzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, etc., but not limited thereto. The pharmaceutical combination of the present invention may comprise a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, etc. in addition to the above components.
The ap-propriate pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
[42] As another embodiment, the present invention provides a method for treating a cancer comprising administering the pharmaceutical combination into an individual who needs it. In the present invention, the "individual" includes mammals, particularly humans.
Mode for the Invention [43] Hereinafter, the configuration and effect of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.
[44] <Example 1: Confirmation of anti-cancer effect of the combination of the present invention using bortezomib as the second active ingredient, in MM. is xenograft model>
[45] 1-1)Experimental method [46] a.Preparation of animal tumor model [47] MM. is which is a human multiple myeloma cell line was purchased from ATCC
(USA). MM. is cell line was maintained with RPMI1640 (Gibco, USA) containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA).
[48] After MM. is cells which were mixed with matrigel were subcutaneously ad-ministered into NOD.CB17-Prkdcscid/NCrHsd male mouse (2x107 cell/head) to organize groups to uniformly distribute the tumor size and then used in the experiment.
[49] b.Preparation of active ingredients [50] The compound of the chemical formula 1 was prepared in the concentration of 4 mg/
ml by dissolving with physiological saline solution.
[51] Bortezomib was prepared in the concentration of 0.005 mg/ml by dissolving with physiological saline solution.
[52] Dexamethasone was prepared in the concentration of 0.05 mg/ml by diluting 5 mg/
mL original solution with physiological saline solution.
[53] The using solution was prepared on the day of use, and the remaining solution was discarded.
[54] c.Confirmation of anti-tumor activity [55] The anti-cancer effect of the compound of the chemical formula 1 and bortezomib and dexamethasone was evaluated in MM. is xenograft model. The experimental groups were divided to the following different administration groups.
[56] - control group: vehicle [57] - Chemical formula 1: the compound of the chemical formula 1 (40 mg/kg, once a week, injection) [58] - Combination group of bortezomib and dexamethasone : bortezomib (0.05 mg/kg, twice a week, injection), dexamethasone (0.5 mg/kg, 4 times a week, injection) [59] - Combination group of chemincal formula 1, bortezomib and dexamethasone : the compound of the chemical formula 1 (40 mg/kg, once a week, injection), bortezomib (0.05 mg/kg, twice a week, injection), dexamethasone (0.5 mg/kg, 4 times a week, injection) [60] All experimental groups were administered intraperitoneally for 57 days. The toxicity was monitored by measuring mouse weight, and the tumor growth was measured by using caliper during the experiment. The tumor volume was calculated according to the following mathematical equation 1.
[61] [Mathematical equation 1]
[62] tumor volume = (length x width2) /2 [63] d.Statistical analysis [64] For all the results of the present experiment, the comparison between experimental groups was performed by assuming normality of the data through parametric multiple comparison or nonparametric multiple comparison, and statistical analysis was performed by using Prism 5.03 (GraphPad Software Inc., San Diego, CA, USA), and the case where p value was below 0.05 was considered statistically significant.
[65] 1-2)Experimental result [66] In order to evaluate anti-tumor effect by coadministration of the compound of the chemical formula 1 and bortezomib, dexamethasone, each substance was administered into xenograft mouse, and the weight and tumor growth were monitored for 57 days.
[67] In an aspect of tumor growth inhibiting effect, comparing the tumor sizes of group administering the compound of the chemical formula 1 and coadministration group of bortezomib and dexamethasone, and coadministration group of the compound of the chemical formula 1+bortezomib+dexamethasone to a group administering an excipient during administration period, the tumor growth was highly inhibited.
[68] In the coadministration group of bortezomib and dexamethasone, there was a slight decrease in the size, but the number of mice reaching a complete remission was only 1, and most of the mice had an effect of reducing the cancer less than 50%.
While, in the coadministration group of the compound of the chemical formula 1+bortezomib+dexamethasone, the complete remission was observed in 3 mice, and most of the mice had an effect of reducing the cancer more than 50%. It is a very surprising effect that cancer reaches complete remission, and the increase of the rate of complete remission suggests that the combination of these drugs is very beneficial.
[69] These results suggest that the anti-cancer effect of 3-agent combination therapy of the compound of the chemical formula Lbortezomib and dexamethasone is very ex-ceptional.
[70] <Example 2:Confirmation of anti-cancer effect of the combination of the present invention using lenalidomide as the second active ingredient, in MM.
is xenograft model>
[71] 2-1)Experimental method [72] a.Preparation of animal tumor model [73] MM. is which is a human multiple myeloma cell line was purchased from ATCC
(USA). MM. is cell line was maintained with RPMI1640 (Gibco, USA) containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA).
[74] After MM. is cells which were mixed with matrigel were subcutaneously ad-ministered into NOD.CB17-Prkdcscid/NCrHsd male mouse (2x107 cell/head) to organize groups to uniformly distribute the tumor size and then used in the experiment.
[75] b.Preparation of active ingredients [76] The compound of the chemical formula 1 was prepared in the concentration of 6 mg/
ml by dissolving with physiological saline solution.
[77] Lenalidomide was prepared in the concentration of 1 mg/ml by dissolving with 1%
HC1 in PBS, and then titrating to a neutral pH.
[78] Dexamethasone was prepared in the concentration of 0.2 mg/ml by diluting 5 mg/ml dexamethasone with saline.
[79] The using solution was prepared on the day of use, and the remaining solution was discarded.
[80] c.Confirmation of anti-tumor activity [81] The anti-cancer effect of the compound of the chemical formula 1 and lenalidomide and dexamethasone was evaluated in MM. is xenograft model. The experimental groups were divided to the following different administration groups.
[82] - control group: vehicle [83] - group administering only the compound of the chemical formula 1 :
the compound of the chemical formula 1 (60 mg/kg, once a week, injection) [84] - coadministration group of lenalidomide and dexamethasone:
lenalidomide (10 mg/
kg, once a day, injection), dexamethasone (2 mg/kg, once a week, injection) [85] - coadministration group : the compound of the chemical formula 1 (60 mg/kg, once a week, injection), lenalidomide (10 mg/kg, once a day, injection), dexamethasone (2 mg/kg, once a week, injection) [86] All experimental groups were administered intraperitoneally for 70 days. The toxicity was monitored by measuring mouse weight, and the tumor growth was measured by using caliper during the experiment. The tumor volume was calculated according to the mathematical equation 1 in Example 1.
[87] d.Statistical analysis [88] For all the results of the present experiment, the comparison between experimental groups was performed by assuming normality of the data through parametric multiple comparison or nonparametric multiple comparison, and statistical analysis was performed by using Prism 5.03 (GraphPad Software Inc., San Diego, CA, USA), and the case where p value was below 0.05 was considered statistically significant.
[89] 2-2)Experimental result [90] In order to evaluate anti-tumor effect by coadministration of the compound of the chemical formula 1 and lenalidomide, dexamethasone, each substance was ad-ministered into xenograft mouse, and the weight and tumor growth were monitored for 70 days.
[91] In an aspect of tumor growth inhibiting effect, comparing the tumor sizes of group administering the compound of the chemical formula 1 and coadministration group of lenalidomide and dexamethasone, and coadministration group of the compound of the chemical formula 1+ lenalidomide+dexamethasone to a group administering an excipient during administration period, the tumor growth was highly inhibited.
[92] In the coadministration group of lenalidomide and dexamethasone, there was a slight increase in the size of the first cancer, while in the coadministration group of the compound of the chemical formula 1+ lenalidomide+dexamethasone, most of the mice had an effect of reducing the cancer including complete remission.
[93] These results suggest that the anti-cancer effect of 3-agent coadministration therapy of the compound of the chemical formula 1 and lenalidomide, dexamethasone is very high.
Generally, it is known that the compound of the above chemical formula 1 ad-ministered to humans varies in dosage depending on various administration factors including individual specific factors of patients, but for example, it can be administered in 10 to 210 mg/m2.
[22] On the other hand, the second active ingredient of the pharmaceutical combination according to the present invention is a proteasome inhibitor or an immunomodulatory drug, and the proteasome inhibitor is an agent inhibiting activity of a proteasome (i.e. a cell complex degrading a protein) degrading a cell division regulating protein reversely, and it is based on the fact that the normal cells regenerate cell division ability even if the activity of the proteasome is temporarily inhibited, but various cancer cells enter the death process as soon as the proteasome activity is temporarily inhibited. The proteasome inhibitor that may be comprised in the pharmaceutical com-bination of the present invention may be various classes of known proteasome in-hibitors. For example, as a class of peptide boronate, there is bortezomib (INN, PS0341; Velcade) which is a compound approved in the United States for treating relapsed multiple myeloma. There is CEP-18770, as another peptide boronate. As other classes of proteasome inhibitors, there are peptide aldehyde (for example, MG132), peptide vinyl sulfone, peptide epoxyketone (for example, epoxomicin, carfilzomib), p lactone inhibitor (for example, lactocystine, MLN 519, NPI-0052, salinosporamide A), a compound which produces dithiocarbamate complex with a metal (for example, disulfiram which is also used in treatment of chronic alcoholism), and specific an-tioxidant (for example, epigallocatechin-3-gallate, catechin-3-galate, and sali-nosporamide A. The proteasome inhibitor comprised in the pharmaceutical com-bination of the present invention is preferably, bortezomib represented by the following chemical formula 2 or its pharmaceutically acceptable salt. The bortezomib can be administered intravenously or subcutaneously in a dose of 0.3-1.5 mg/m2, 1 to 2 times per week, depending on the administration schedule, but is not limited thereto.
[23] [Chemical formula 21 [24]
0004,4%.
N
[251 Meanwhile, the immunomodulatory drug has effects such as expansion of immune cells and promotion of tumor cell death, etc. and specifically, a substance which regulates immunity by improving ADCC (antibody-dependent cell-mediated cyto-toxicity). Specifically, the immunomodulatory drug comprised in the pharmaceutical combination of the present invention may be thalidomide lenalidomide, for-malidomide, or a pharmaceutically acceptable salt, and preferably, lenalidomide rep-resented by the following chemical formula 3 or its pharmaceutically acceptable salt.
Lenalidomide is generally orally administered in a dose of 10 mg to 30 mg depending on the administration schedule, but is not limited thereto.
[26] [Chemical formula 31 [27]
a [28]
[29] The third active ingredient of the pharmaceutical combination according to the present invention is a steroidal anti-cancer agent, and for example, may be prednisone or dexamethasone, but is not limited thereto. Preferably, dexamethasone represented by the following chemical formula 4 that is, (8S, 9R, 10S, 11S, 13S, 14S, 16R, 17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacety1)-10,13,16-trimethy1-6,7,8,9,10,11 ,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene- 3-on or isotope variant; or its pharmaceutically acceptable salt, hydrate, or solvate. In one em-bodiment, dexamethasone is (8S, 9R, 10S, 11S, 13S, 14S, 16R, 17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacety1)-10,13,16-trimethy1-6,7,8,9,10,11 ,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3-on. In other em-bodiment, dexamethasone is (8S, 9R, 10S, 11S, 13S, 14S, 16R, 17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacety1)-10,13,16-trimethy1-6,7,8,9,10,11 ,12,13,14,15,16,17- dodecahydro-3H-cyclopenta[a]phenanthrene-3-on, wherein hydrogen atom is deuterated.
[30] [Chemical formula 41 [31]
V 1' O 0 H
[32] In the present invention, the pharmaceutically acceptable salt means a salt commonly used in the medical industry, and for example, there are inorganic ionic salts prepared with calcium, potassium, sodium and magnesium, etc., inorganic acid salts prepared with hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid, tartaric acid and sulfuric acid, etc., organic acid salts prepared with acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, etc., amino acid salts prepared with methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, p-toluene sulfonic acid and naphthalene sulfonic acid, etc., and amine salts prepared with trimethylamine, triethylamine, ammonia, pyridine, picoline, etc., but the kinds of salts in the present invention are not limited by these listed salts.
[33] In one specific embodiment, the first active ingredient, the second active ingredient, and the third active ingredient may be comprised per 100 parts by weight of the total pharmaceutical combination. When a proteasome inhibitor such as bortezomib is used as the second active ingredient, it is composed of 28.55 to 85.60 parts by weight of the first active ingredient, 1.28 to 8.63 parts by weight of the second active ingredient and 2.71 to 69.55 parts by weight of the third active ingredient. When an im-munomodulatory drug such as lenalidomide is used as the second active ingredient, it is composed of 19.54 to 94.69 parts by weight of the first active ingredient, 2.46 to 52.63 parts by weight of the second active ingredient and 2.52 to 59.70 parts by weight of the third active ingredient.
[34] The pharmaceutical combination may comprise 3 kinds of separate formulations, and may consist of two or one formulation.
[35] The combination of the present invention may be administered orally or parenterally (For example, intravenously, subcutaneously, intraperitoneally or topically).
In the present invention, the first active ingredient and the second active ingredient may be administered orally or parenterally, and preferably, may be administered parenterally.
In addition, the third active ingredient may be parenterally or orally administered, preferably administered orally.
[36] In the combination of the present invention, the range of appropriate dose of the first active ingredient to the third active ingredient varies according to the body weight, age, sex, health condition of patient, diet, administration time, administration method, excretion rate, and severity of disease, etc. The daily dose of the first active ingredient is approximately 10 ¨ 80 mg/kg, preferably 20 to 60 mg/kg. In addition, the daily dose of the second active ingredient of the present invention is approximately 0.1 ¨ 5 mg/
kg, preferably 0.5 to 2 mg/kg.
[37] In the combination of the present invention, the appropriate administration period of the first active ingredient and the second active ingredient and the third active in-gredient may be determined according to the dose. For example, in case that the second active ingredient of the present invention is a proteasome inhibitor, the first active in-gredient may be administered once a day to once every two weeks, preferably once a week. In addition, the second active ingredient of the present invention may be ad-ministered once a day to once a week, preferably twice a week. The third active in-gredient of the present invention may be administered once a day to once a week, preferably 4 times a week. In addition, in case that the second active ingredient of the present invention is an immunomodulatory drug, the first active ingredient of the present invention may be administered once a day to once every two weeks, preferably once a week, and the second active ingredient may be administered once a day to once a week, preferably once a day, and the third active ingredient may be administered once a day to once a week, preferable once a week.
[38] The pharmaceutical combination of the present invention confirmed the combination effect of the first active ingredient, which is a HDAC inhibitor, the second active in-gredient, which is a proteasome inhibitor or an immunomodulatory drug, and the third active ingredient, which is a steroidal anti-cancer agent, thereby exhibiting excellent anti-cancer activity.
[39] Therefore, the anti-cancer combination of the present invention can by usefully used as an anti-cancer treatment strategy, and it is preferable particularly for treating a hematological cancer. The hematological cancer may preferably be multiple myeloma.
[40] In the present invention, the first active ingredient, the second active ingredient, and the third active ingredient comprised in the combination of the present invention may be comprised in separate pharmaceutical composition respectively, and the pharma-ceutical composition may be prepared in a unit dose form or prepared by introducing in a multi-dose container by formulating it using a pharmaceutically acceptable carrier, according to a method which can be easily carried out by a person having ordinary skill in the art.
[41] The pharmaceutically acceptable carrier is conventionally used in formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxy-benzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, etc., but not limited thereto. The pharmaceutical combination of the present invention may comprise a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, etc. in addition to the above components.
The ap-propriate pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
[42] As another embodiment, the present invention provides a method for treating a cancer comprising administering the pharmaceutical combination into an individual who needs it. In the present invention, the "individual" includes mammals, particularly humans.
Mode for the Invention [43] Hereinafter, the configuration and effect of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.
[44] <Example 1: Confirmation of anti-cancer effect of the combination of the present invention using bortezomib as the second active ingredient, in MM. is xenograft model>
[45] 1-1)Experimental method [46] a.Preparation of animal tumor model [47] MM. is which is a human multiple myeloma cell line was purchased from ATCC
(USA). MM. is cell line was maintained with RPMI1640 (Gibco, USA) containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA).
[48] After MM. is cells which were mixed with matrigel were subcutaneously ad-ministered into NOD.CB17-Prkdcscid/NCrHsd male mouse (2x107 cell/head) to organize groups to uniformly distribute the tumor size and then used in the experiment.
[49] b.Preparation of active ingredients [50] The compound of the chemical formula 1 was prepared in the concentration of 4 mg/
ml by dissolving with physiological saline solution.
[51] Bortezomib was prepared in the concentration of 0.005 mg/ml by dissolving with physiological saline solution.
[52] Dexamethasone was prepared in the concentration of 0.05 mg/ml by diluting 5 mg/
mL original solution with physiological saline solution.
[53] The using solution was prepared on the day of use, and the remaining solution was discarded.
[54] c.Confirmation of anti-tumor activity [55] The anti-cancer effect of the compound of the chemical formula 1 and bortezomib and dexamethasone was evaluated in MM. is xenograft model. The experimental groups were divided to the following different administration groups.
[56] - control group: vehicle [57] - Chemical formula 1: the compound of the chemical formula 1 (40 mg/kg, once a week, injection) [58] - Combination group of bortezomib and dexamethasone : bortezomib (0.05 mg/kg, twice a week, injection), dexamethasone (0.5 mg/kg, 4 times a week, injection) [59] - Combination group of chemincal formula 1, bortezomib and dexamethasone : the compound of the chemical formula 1 (40 mg/kg, once a week, injection), bortezomib (0.05 mg/kg, twice a week, injection), dexamethasone (0.5 mg/kg, 4 times a week, injection) [60] All experimental groups were administered intraperitoneally for 57 days. The toxicity was monitored by measuring mouse weight, and the tumor growth was measured by using caliper during the experiment. The tumor volume was calculated according to the following mathematical equation 1.
[61] [Mathematical equation 1]
[62] tumor volume = (length x width2) /2 [63] d.Statistical analysis [64] For all the results of the present experiment, the comparison between experimental groups was performed by assuming normality of the data through parametric multiple comparison or nonparametric multiple comparison, and statistical analysis was performed by using Prism 5.03 (GraphPad Software Inc., San Diego, CA, USA), and the case where p value was below 0.05 was considered statistically significant.
[65] 1-2)Experimental result [66] In order to evaluate anti-tumor effect by coadministration of the compound of the chemical formula 1 and bortezomib, dexamethasone, each substance was administered into xenograft mouse, and the weight and tumor growth were monitored for 57 days.
[67] In an aspect of tumor growth inhibiting effect, comparing the tumor sizes of group administering the compound of the chemical formula 1 and coadministration group of bortezomib and dexamethasone, and coadministration group of the compound of the chemical formula 1+bortezomib+dexamethasone to a group administering an excipient during administration period, the tumor growth was highly inhibited.
[68] In the coadministration group of bortezomib and dexamethasone, there was a slight decrease in the size, but the number of mice reaching a complete remission was only 1, and most of the mice had an effect of reducing the cancer less than 50%.
While, in the coadministration group of the compound of the chemical formula 1+bortezomib+dexamethasone, the complete remission was observed in 3 mice, and most of the mice had an effect of reducing the cancer more than 50%. It is a very surprising effect that cancer reaches complete remission, and the increase of the rate of complete remission suggests that the combination of these drugs is very beneficial.
[69] These results suggest that the anti-cancer effect of 3-agent combination therapy of the compound of the chemical formula Lbortezomib and dexamethasone is very ex-ceptional.
[70] <Example 2:Confirmation of anti-cancer effect of the combination of the present invention using lenalidomide as the second active ingredient, in MM.
is xenograft model>
[71] 2-1)Experimental method [72] a.Preparation of animal tumor model [73] MM. is which is a human multiple myeloma cell line was purchased from ATCC
(USA). MM. is cell line was maintained with RPMI1640 (Gibco, USA) containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA).
[74] After MM. is cells which were mixed with matrigel were subcutaneously ad-ministered into NOD.CB17-Prkdcscid/NCrHsd male mouse (2x107 cell/head) to organize groups to uniformly distribute the tumor size and then used in the experiment.
[75] b.Preparation of active ingredients [76] The compound of the chemical formula 1 was prepared in the concentration of 6 mg/
ml by dissolving with physiological saline solution.
[77] Lenalidomide was prepared in the concentration of 1 mg/ml by dissolving with 1%
HC1 in PBS, and then titrating to a neutral pH.
[78] Dexamethasone was prepared in the concentration of 0.2 mg/ml by diluting 5 mg/ml dexamethasone with saline.
[79] The using solution was prepared on the day of use, and the remaining solution was discarded.
[80] c.Confirmation of anti-tumor activity [81] The anti-cancer effect of the compound of the chemical formula 1 and lenalidomide and dexamethasone was evaluated in MM. is xenograft model. The experimental groups were divided to the following different administration groups.
[82] - control group: vehicle [83] - group administering only the compound of the chemical formula 1 :
the compound of the chemical formula 1 (60 mg/kg, once a week, injection) [84] - coadministration group of lenalidomide and dexamethasone:
lenalidomide (10 mg/
kg, once a day, injection), dexamethasone (2 mg/kg, once a week, injection) [85] - coadministration group : the compound of the chemical formula 1 (60 mg/kg, once a week, injection), lenalidomide (10 mg/kg, once a day, injection), dexamethasone (2 mg/kg, once a week, injection) [86] All experimental groups were administered intraperitoneally for 70 days. The toxicity was monitored by measuring mouse weight, and the tumor growth was measured by using caliper during the experiment. The tumor volume was calculated according to the mathematical equation 1 in Example 1.
[87] d.Statistical analysis [88] For all the results of the present experiment, the comparison between experimental groups was performed by assuming normality of the data through parametric multiple comparison or nonparametric multiple comparison, and statistical analysis was performed by using Prism 5.03 (GraphPad Software Inc., San Diego, CA, USA), and the case where p value was below 0.05 was considered statistically significant.
[89] 2-2)Experimental result [90] In order to evaluate anti-tumor effect by coadministration of the compound of the chemical formula 1 and lenalidomide, dexamethasone, each substance was ad-ministered into xenograft mouse, and the weight and tumor growth were monitored for 70 days.
[91] In an aspect of tumor growth inhibiting effect, comparing the tumor sizes of group administering the compound of the chemical formula 1 and coadministration group of lenalidomide and dexamethasone, and coadministration group of the compound of the chemical formula 1+ lenalidomide+dexamethasone to a group administering an excipient during administration period, the tumor growth was highly inhibited.
[92] In the coadministration group of lenalidomide and dexamethasone, there was a slight increase in the size of the first cancer, while in the coadministration group of the compound of the chemical formula 1+ lenalidomide+dexamethasone, most of the mice had an effect of reducing the cancer including complete remission.
[93] These results suggest that the anti-cancer effect of 3-agent coadministration therapy of the compound of the chemical formula 1 and lenalidomide, dexamethasone is very high.
Claims (13)
- [Claim 1] A combination for treating a hematological cancer comprising, 1) a compound of the following chemical formula 1 or its pharma-ceutically acceptable salt as the first active ingredient;
2) a proteasome inhibitor or an immunomodulatory drug as the second active ingredient; and 3) a steroidal anti-cancer agent as the third active ingredient:
- [Claim 2] The combination of claim 1, wherein the proteasome inhibitor is bortezomib of the following chemical formula 2 or its pharmaceutically acceptable salt:
[Chemical formula 2]
- [Claim 3] The combination of claim 1, wherein the immunomodulatory drug is lenalidomide of the following chemical formula 3 or its pharma-ceutically acceptable salt:
[Chemical formula 3]
- [Claim 4] The combination of claim 1, wherein the steroidal anti-cancer agent is dexamethasone of the following chemical formula 4 or its pharma-ceutically acceptable salt:
[Chemical formula 4]
- [Claim 5] The combination of claim 1, wherein the pharmaceutically acceptable salt of the compound of the chemical formula 1 is methanesulfonate.
- [Claim 6] The combination of claim 3, wherein the lenalidomide is lenalidomide free base.
- [Claim 7] The combination of claim 1, wherein the second active ingredient is a proteasome inhibitor, and the first active ingredient, the second active ingredient, and the third active ingredient are comprised in an amount of 28.55-85.60 parts by weight of the first active ingredient, 1.28-8.63 parts by weight of the second active ingredient, and 2.71-69.55 parts by weight of the third active ingredient, per 100 parts by weight of the total pharmaceutical combination.
- [Claim 8] The combination of claim 1, wherein the second active ingredient is an immunomodulatory drug, and the first active ingredient, the second active ingredient, and the third active ingredient are comprised in an amount of 19.54-94.69 parts by weight of the first active ingredient, 2.46-52.63 parts by weight of the second active ingredient, and 2.52-59.70 parts by weight of the third active ingredient, per 100 parts by weight of the total pharmaceutical combination.
- [Claim 9] The combination of claim 1, wherein the hematological cancer is multiple myeloma.
- [Claim 10] The combination of claim 1, wherein the first active ingredient, the second active ingredient, and the third active ingredient are comprised in the form of separate formulations respectively.
- [Claim 11] The combination of claim 1, wherein the first active ingredient, the second active ingredient, and the third active ingredient are combined and comprised in the form of a single formulation.
- [Claim 12] The combination of claim 10, wherein the first active ingredient and the second active ingredient are comprised as a formulation in a parenteral administration form, and the third active ingredient is comprised as a formulation in an oral administration form.
- [Claim 13] The combination of claim 10 or claim 12, wherein the formulation comprising the first active ingredient and the formulation comprising the second active ingredient, and the formulation comprising the third active ingredient of the combination are in the form of a formulation that can be administered simultaneously or sequentially.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0127767 | 2016-10-04 | ||
| KR1020160127767A KR102002581B1 (en) | 2016-10-04 | 2016-10-04 | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer |
| PCT/KR2017/011015 WO2018066946A1 (en) | 2016-10-04 | 2017-09-29 | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3038019A1 true CA3038019A1 (en) | 2018-04-12 |
Family
ID=61832016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3038019A Pending CA3038019A1 (en) | 2016-10-04 | 2017-09-29 | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3522891A4 (en) |
| JP (2) | JP2019529562A (en) |
| KR (1) | KR102002581B1 (en) |
| CN (1) | CN109789138A (en) |
| AU (1) | AU2017338564B2 (en) |
| BR (1) | BR112019006633A2 (en) |
| CA (1) | CA3038019A1 (en) |
| MX (1) | MX2019003907A (en) |
| RU (1) | RU2721409C1 (en) |
| WO (1) | WO2018066946A1 (en) |
| ZA (1) | ZA201902340B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7415973B2 (en) | 2021-02-12 | 2024-01-17 | 信越化学工業株式会社 | Chemically amplified positive resist composition and resist pattern forming method |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781639B1 (en) * | 2004-07-28 | 2012-01-25 | Janssen Pharmaceutica NV | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| JP5377968B2 (en) * | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | Histone deacetylase (HDAC) inhibitors used alone or in combination with chemotherapeutic drugs for cancer treatment |
| MX2009002925A (en) * | 2006-09-15 | 2009-03-31 | Janssen Pharmaceutica Nv | Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors. |
| EP2389068A4 (en) * | 2009-01-23 | 2012-07-18 | Cancer Rec Tech Ltd | Hedgehog pathway inhibitors |
| KR101168801B1 (en) * | 2009-03-27 | 2012-07-25 | 주식회사종근당 | Novel hydroxamate derivatives, method for the preparation thereof, and pharmaceutical composition containing the same |
| WO2010124009A2 (en) * | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| US8610434B2 (en) | 2011-07-21 | 2013-12-17 | ColdEdge Technologies, Inc. | Cryogen-free cooling system for electron paramagnetic resonance system |
| WO2013021032A1 (en) * | 2011-08-11 | 2013-02-14 | Janssen Pharmaceutica Nv | Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone |
| NZ628078A (en) * | 2012-08-09 | 2017-01-27 | Celgene Corp | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| CR20160200A (en) * | 2013-10-11 | 2016-08-29 | Acetylon Pharmaceuticals Inc | COMBINATIONS OF HISTONE DEACETILASE INHIBITORS AND IMMUNOMODULATING DRUGS |
| TR201900057T4 (en) * | 2013-12-12 | 2019-01-21 | Chong Kun Dang Pharmaceutical Corp | New azaindole derivatives and pharmaceutical compositions containing them as selective histone deacetylase (HDAC) inhibitors. |
-
2016
- 2016-10-04 KR KR1020160127767A patent/KR102002581B1/en active IP Right Grant
-
2017
- 2017-09-29 CN CN201780061019.9A patent/CN109789138A/en active Pending
- 2017-09-29 CA CA3038019A patent/CA3038019A1/en active Pending
- 2017-09-29 JP JP2019537733A patent/JP2019529562A/en active Pending
- 2017-09-29 RU RU2019108930A patent/RU2721409C1/en active
- 2017-09-29 AU AU2017338564A patent/AU2017338564B2/en not_active Ceased
- 2017-09-29 WO PCT/KR2017/011015 patent/WO2018066946A1/en unknown
- 2017-09-29 EP EP17858740.8A patent/EP3522891A4/en not_active Withdrawn
- 2017-09-29 MX MX2019003907A patent/MX2019003907A/en unknown
- 2017-09-29 BR BR112019006633A patent/BR112019006633A2/en not_active Application Discontinuation
-
2019
- 2019-04-12 ZA ZA2019/02340A patent/ZA201902340B/en unknown
-
2020
- 2020-10-28 JP JP2020180411A patent/JP2021020953A/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019003907A (en) | 2019-08-05 |
| JP2021020953A (en) | 2021-02-18 |
| JP2019529562A (en) | 2019-10-17 |
| WO2018066946A1 (en) | 2018-04-12 |
| AU2017338564A1 (en) | 2019-05-02 |
| AU2017338564B2 (en) | 2020-07-09 |
| BR112019006633A2 (en) | 2019-07-02 |
| ZA201902340B (en) | 2020-08-26 |
| CN109789138A (en) | 2019-05-21 |
| KR20180037507A (en) | 2018-04-12 |
| EP3522891A4 (en) | 2020-04-15 |
| KR102002581B1 (en) | 2019-07-22 |
| EP3522891A1 (en) | 2019-08-14 |
| RU2721409C1 (en) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1701725B1 (en) | Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain | |
| EP3157531B1 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
| AU2014250795B2 (en) | Cancer therapy | |
| JP2011140521A (en) | Drug for mitigating taxane-induced neurotoxicity | |
| JP2008505139A (en) | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting | |
| EA030335B1 (en) | Use of amisulpride as an anti-emetic | |
| KR20200096141A (en) | Composition for preventing or treating colon cancer comprising streptonigrin and anticancer agent | |
| Zullo et al. | Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice | |
| WO2017148129A1 (en) | Pharmaceutical composition for treating cachexia and use thereof | |
| CA3038019A1 (en) | Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer | |
| US20240016790A1 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| JP2019527707A (en) | Methods for treating and preventing side effects of cancer treatment | |
| EP3592351B1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| CN107613966A (en) | The combination of opioid and N acyl ethanol amines | |
| JP7527662B2 (en) | Pharmaceutical compositions of pimozide and methotrexate and uses thereof | |
| CN117177772A (en) | Therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance | |
| RU2724341C1 (en) | Combined composition for preventing or treating cancer, containing benzophenone-thiazole derivatives as vda and topoisomerase inhibitor | |
| KR101828997B1 (en) | A pharmaceutical composition for prevention or treatment of cancer and use thereof | |
| KR101824205B1 (en) | A pharmaceutical composition for prevention or treatment of cancer and use thereof | |
| JP2019131559A (en) | Combination of pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of cancer of head and neck | |
| IE20150193A1 (en) | Kinetin (N6-Furfuryadenine) for preventing and treating mucositis and proctitis and erythemia | |
| WO2023227592A1 (en) | Method for pretreating relapsing cancer | |
| Gleason et al. | Treatment of emergent peripheral neuropathy in plasma cell disorders | |
| WO2019240632A1 (en) | Agent having anti-tumor effect for treating oncological diseases | |
| BR112015002384B1 (en) | PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR AND AN EGFR INHIBITOR, AND THEIR USES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190322 |
|
| EEER | Examination request |
Effective date: 20190322 |
|
| EEER | Examination request |
Effective date: 20190322 |
|
| EEER | Examination request |
Effective date: 20190322 |
|
| EEER | Examination request |
Effective date: 20190322 |
|
| EEER | Examination request |
Effective date: 20190322 |